MASLD-A multi-omic study of microbiome and metabolic dysfunction-associated steatotic liver disease (human)
Leveraging a large-scale collection of stool specimens in the Micro-N study within the prospective cohort study (Nurses' Health Study II), we performed shotgun metagenomic sequencing and untargeted metabolomics profiling among 211 women with metabolic dysfunction-associated steatotic liver disease (MASLD), matched to age-, body mass index-, and location-matched healthy controls (total N with matched and unmatched controls=713). We found microbiome and metabolomic profiles to be altered in MASLD cases compared to controls. Data deposited include metagenomic sequencing data (after removing the human sequences) and metabolomics data.